Details
Stereochemistry | ACHIRAL |
Molecular Formula | C14H14ClNS |
Molecular Weight | 263.786 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
ClC1=C(CN2CCC3=C(C2)C=CS3)C=CC=C1
InChI
InChIKey=PHWBOXQYWZNQIN-UHFFFAOYSA-N
InChI=1S/C14H14ClNS/c15-13-4-2-1-3-11(13)9-16-7-5-14-12(10-16)6-8-17-14/h1-4,6,8H,5,7,9-10H2
Molecular Formula | C14H14ClNS |
Molecular Weight | 263.786 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Ticlopidine (trade name Ticlid) is an antiplatelet drug in the thienopyridine family which is an adenosine diphosphate (ADP) receptor inhibitor. Ticlopidine is a prodrug that is metabolized to an as yet undetermined metabolite that acts as a platelet aggregation inhibitor. Inhibition of platelet aggregation causes a prolongation of bleeding time. In its prodrug form, ticlopidine has no significance in vitro activity at the concentrations attained in vivo. The active metabolite of ticlopidine prevents binding of adenosine diphosphate (ADP) to its platelet receptor, impairing the ADP-mediated activation of the glycoprotein GPIIb/IIIa complex. It is proposed that the inhibition involves a defect in the mobilization from the storage sites of the platelet granules to the outer membrane. No direct interference occurs with the GPIIb/IIIa receptor. As the glycoprotein GPIIb/IIIa complex is the major receptor for fibrinogen, its impaired activation prevents fibrinogen binding to platelets and inhibits platelet aggregation. Ticlopidine is FDA approved for the prevention of strokes and, when combined with aspirin, for patients with a new coronary stent to prevent closure. There are also several off-label uses, including acute treatment of myocardial infarction and unstable angina, peripheral vascular disease, prevention of myocardial infarctions, diabetic retinopathy, and sickle cell disease. The most serious side effects associated with ticlopidine are those that affect the blood cells, although these life-threatening complications are relatively rare.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: GO:0070527 |
|||
Target ID: CHEMBL2001 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15852221 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Preventing | TICLID Approved UseTiclopidine hydrochloride tablets are indicated: to reduce the risk of thrombotic stroke (fatal or nonfatal) in patients who have experienced stroke precursors, and in patients who have had a completed thrombotic stroke. Because ticlopidine is associated with a risk of life-threatening blood dyscrasias including thrombotic thrombocytopenic purpura (TTP), neutropenia/agranulocytosis and aplastic anemia (see BOX WARNING and WARNINGS ), ticlopidine should be reserved for patients who are intolerant or allergic to aspirin therapy or who have failed aspirin therapy. as adjunctive therapy with aspirin to reduce the incidence of subacute stent thrombosis in patients undergoing successful coronary stent implantation (see CLINICAL TRIALS ). Launch Date6.8886718E11 |
|||
Preventing | TICLID Approved UseTiclopidine hydrochloride tablets are indicated: to reduce the risk of thrombotic stroke (fatal or nonfatal) in patients who have experienced stroke precursors, and in patients who have had a completed thrombotic stroke. Because ticlopidine is associated with a risk of life-threatening blood dyscrasias including thrombotic thrombocytopenic purpura (TTP), neutropenia/agranulocytosis and aplastic anemia (see BOX WARNING and WARNINGS ), ticlopidine should be reserved for patients who are intolerant or allergic to aspirin therapy or who have failed aspirin therapy. as adjunctive therapy with aspirin to reduce the incidence of subacute stent thrombosis in patients undergoing successful coronary stent implantation (see CLINICAL TRIALS ). Launch Date6.8886718E11 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
365.3 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/12419644 |
250 mg single, oral dose: 250 mg route of administration: Oral experiment type: SINGLE co-administered: |
TICLOPIDINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1053.9 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/12419644 |
250 mg single, oral dose: 250 mg route of administration: Oral experiment type: SINGLE co-administered: |
TICLOPIDINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
7.46 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/12419644 |
250 mg single, oral dose: 250 mg route of administration: Oral experiment type: SINGLE co-administered: |
TICLOPIDINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2% |
TICLOPIDINE plasma | Homo sapiens |
Doses
Dose | Population | Adverse events |
---|---|---|
200 mg 1 times / day multiple, oral Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: |
unhealthy, 64.7 n = 578 Health Status: unhealthy Condition: stroke Age Group: 64.7 Sex: M+F Population Size: 578 Sources: |
Other AEs: Leukopenia, Neutropenia... Other AEs: Leukopenia (4 patients) Sources: Neutropenia (14 patients) Aspartate aminotransferase increased (13 patients) ALT increased (36 patients) Gamma GT increased (54 patients) ALP increased (2 patients) Cerebral hemorrhage (1 patient) Gastric ulcer hemorrhage (1 patient) Melena (1 patient) Epistaxis (2 patients) Rash (1 patient) |
250 mg 2 times / day multiple, oral Recommended Dose: 250 mg, 2 times / day Route: oral Route: multiple Dose: 250 mg, 2 times / day Sources: |
unhealthy, 70 n = 1 Health Status: unhealthy Condition: stroke Age Group: 70 Sex: F Population Size: 1 Sources: |
Disc. AE: Agranulocytosis, AST increased... AEs leading to discontinuation/dose reduction: Agranulocytosis (1 patient) Sources: AST increased (1 patient) ALT increased (1 patient) Gamma GT increased (1 patient) ALP increased (1 patient) |
250 mg 2 times / day multiple, oral Recommended Dose: 250 mg, 2 times / day Route: oral Route: multiple Dose: 250 mg, 2 times / day Sources: |
unhealthy, adult n = 2048 Health Status: unhealthy Condition: stroke Age Group: adult Population Size: 2048 Sources: |
Disc. AE: Diarrhea, Nausea... AEs leading to discontinuation/dose reduction: Diarrhea (12.5%) Sources: Nausea (7%) Dyspepsia (7%) Rash (5.1%) GI pain (3.7%) Neutropenia (2.4%) Purpura (2.2%) Vomiting (1.9%) Flatulence (1.5%) Pruritus (1.3%) Dizziness (1.1%) Anorexia (1%) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Cerebral hemorrhage | 1 patient | 200 mg 1 times / day multiple, oral Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: |
unhealthy, 64.7 n = 578 Health Status: unhealthy Condition: stroke Age Group: 64.7 Sex: M+F Population Size: 578 Sources: |
Gastric ulcer hemorrhage | 1 patient | 200 mg 1 times / day multiple, oral Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: |
unhealthy, 64.7 n = 578 Health Status: unhealthy Condition: stroke Age Group: 64.7 Sex: M+F Population Size: 578 Sources: |
Melena | 1 patient | 200 mg 1 times / day multiple, oral Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: |
unhealthy, 64.7 n = 578 Health Status: unhealthy Condition: stroke Age Group: 64.7 Sex: M+F Population Size: 578 Sources: |
Rash | 1 patient | 200 mg 1 times / day multiple, oral Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: |
unhealthy, 64.7 n = 578 Health Status: unhealthy Condition: stroke Age Group: 64.7 Sex: M+F Population Size: 578 Sources: |
Aspartate aminotransferase increased | 13 patients | 200 mg 1 times / day multiple, oral Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: |
unhealthy, 64.7 n = 578 Health Status: unhealthy Condition: stroke Age Group: 64.7 Sex: M+F Population Size: 578 Sources: |
Neutropenia | 14 patients | 200 mg 1 times / day multiple, oral Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: |
unhealthy, 64.7 n = 578 Health Status: unhealthy Condition: stroke Age Group: 64.7 Sex: M+F Population Size: 578 Sources: |
ALP increased | 2 patients | 200 mg 1 times / day multiple, oral Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: |
unhealthy, 64.7 n = 578 Health Status: unhealthy Condition: stroke Age Group: 64.7 Sex: M+F Population Size: 578 Sources: |
Epistaxis | 2 patients | 200 mg 1 times / day multiple, oral Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: |
unhealthy, 64.7 n = 578 Health Status: unhealthy Condition: stroke Age Group: 64.7 Sex: M+F Population Size: 578 Sources: |
ALT increased | 36 patients | 200 mg 1 times / day multiple, oral Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: |
unhealthy, 64.7 n = 578 Health Status: unhealthy Condition: stroke Age Group: 64.7 Sex: M+F Population Size: 578 Sources: |
Leukopenia | 4 patients | 200 mg 1 times / day multiple, oral Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: |
unhealthy, 64.7 n = 578 Health Status: unhealthy Condition: stroke Age Group: 64.7 Sex: M+F Population Size: 578 Sources: |
Gamma GT increased | 54 patients | 200 mg 1 times / day multiple, oral Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: |
unhealthy, 64.7 n = 578 Health Status: unhealthy Condition: stroke Age Group: 64.7 Sex: M+F Population Size: 578 Sources: |
ALP increased | 1 patient Disc. AE |
250 mg 2 times / day multiple, oral Recommended Dose: 250 mg, 2 times / day Route: oral Route: multiple Dose: 250 mg, 2 times / day Sources: |
unhealthy, 70 n = 1 Health Status: unhealthy Condition: stroke Age Group: 70 Sex: F Population Size: 1 Sources: |
ALT increased | 1 patient Disc. AE |
250 mg 2 times / day multiple, oral Recommended Dose: 250 mg, 2 times / day Route: oral Route: multiple Dose: 250 mg, 2 times / day Sources: |
unhealthy, 70 n = 1 Health Status: unhealthy Condition: stroke Age Group: 70 Sex: F Population Size: 1 Sources: |
AST increased | 1 patient Disc. AE |
250 mg 2 times / day multiple, oral Recommended Dose: 250 mg, 2 times / day Route: oral Route: multiple Dose: 250 mg, 2 times / day Sources: |
unhealthy, 70 n = 1 Health Status: unhealthy Condition: stroke Age Group: 70 Sex: F Population Size: 1 Sources: |
Agranulocytosis | 1 patient Disc. AE |
250 mg 2 times / day multiple, oral Recommended Dose: 250 mg, 2 times / day Route: oral Route: multiple Dose: 250 mg, 2 times / day Sources: |
unhealthy, 70 n = 1 Health Status: unhealthy Condition: stroke Age Group: 70 Sex: F Population Size: 1 Sources: |
Gamma GT increased | 1 patient Disc. AE |
250 mg 2 times / day multiple, oral Recommended Dose: 250 mg, 2 times / day Route: oral Route: multiple Dose: 250 mg, 2 times / day Sources: |
unhealthy, 70 n = 1 Health Status: unhealthy Condition: stroke Age Group: 70 Sex: F Population Size: 1 Sources: |
Anorexia | 1% Disc. AE |
250 mg 2 times / day multiple, oral Recommended Dose: 250 mg, 2 times / day Route: oral Route: multiple Dose: 250 mg, 2 times / day Sources: |
unhealthy, adult n = 2048 Health Status: unhealthy Condition: stroke Age Group: adult Population Size: 2048 Sources: |
Dizziness | 1.1% Disc. AE |
250 mg 2 times / day multiple, oral Recommended Dose: 250 mg, 2 times / day Route: oral Route: multiple Dose: 250 mg, 2 times / day Sources: |
unhealthy, adult n = 2048 Health Status: unhealthy Condition: stroke Age Group: adult Population Size: 2048 Sources: |
Pruritus | 1.3% Disc. AE |
250 mg 2 times / day multiple, oral Recommended Dose: 250 mg, 2 times / day Route: oral Route: multiple Dose: 250 mg, 2 times / day Sources: |
unhealthy, adult n = 2048 Health Status: unhealthy Condition: stroke Age Group: adult Population Size: 2048 Sources: |
Flatulence | 1.5% Disc. AE |
250 mg 2 times / day multiple, oral Recommended Dose: 250 mg, 2 times / day Route: oral Route: multiple Dose: 250 mg, 2 times / day Sources: |
unhealthy, adult n = 2048 Health Status: unhealthy Condition: stroke Age Group: adult Population Size: 2048 Sources: |
Vomiting | 1.9% Disc. AE |
250 mg 2 times / day multiple, oral Recommended Dose: 250 mg, 2 times / day Route: oral Route: multiple Dose: 250 mg, 2 times / day Sources: |
unhealthy, adult n = 2048 Health Status: unhealthy Condition: stroke Age Group: adult Population Size: 2048 Sources: |
Diarrhea | 12.5% Disc. AE |
250 mg 2 times / day multiple, oral Recommended Dose: 250 mg, 2 times / day Route: oral Route: multiple Dose: 250 mg, 2 times / day Sources: |
unhealthy, adult n = 2048 Health Status: unhealthy Condition: stroke Age Group: adult Population Size: 2048 Sources: |
Purpura | 2.2% Disc. AE |
250 mg 2 times / day multiple, oral Recommended Dose: 250 mg, 2 times / day Route: oral Route: multiple Dose: 250 mg, 2 times / day Sources: |
unhealthy, adult n = 2048 Health Status: unhealthy Condition: stroke Age Group: adult Population Size: 2048 Sources: |
Neutropenia | 2.4% Disc. AE |
250 mg 2 times / day multiple, oral Recommended Dose: 250 mg, 2 times / day Route: oral Route: multiple Dose: 250 mg, 2 times / day Sources: |
unhealthy, adult n = 2048 Health Status: unhealthy Condition: stroke Age Group: adult Population Size: 2048 Sources: |
GI pain | 3.7% Disc. AE |
250 mg 2 times / day multiple, oral Recommended Dose: 250 mg, 2 times / day Route: oral Route: multiple Dose: 250 mg, 2 times / day Sources: |
unhealthy, adult n = 2048 Health Status: unhealthy Condition: stroke Age Group: adult Population Size: 2048 Sources: |
Rash | 5.1% Disc. AE |
250 mg 2 times / day multiple, oral Recommended Dose: 250 mg, 2 times / day Route: oral Route: multiple Dose: 250 mg, 2 times / day Sources: |
unhealthy, adult n = 2048 Health Status: unhealthy Condition: stroke Age Group: adult Population Size: 2048 Sources: |
Dyspepsia | 7% Disc. AE |
250 mg 2 times / day multiple, oral Recommended Dose: 250 mg, 2 times / day Route: oral Route: multiple Dose: 250 mg, 2 times / day Sources: |
unhealthy, adult n = 2048 Health Status: unhealthy Condition: stroke Age Group: adult Population Size: 2048 Sources: |
Nausea | 7% Disc. AE |
250 mg 2 times / day multiple, oral Recommended Dose: 250 mg, 2 times / day Route: oral Route: multiple Dose: 250 mg, 2 times / day Sources: |
unhealthy, adult n = 2048 Health Status: unhealthy Condition: stroke Age Group: adult Population Size: 2048 Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
moderate [Ki 49 uM] | ||||
no [Ki >1000 uM] | ||||
unlikely [Ki 584 uM] | ||||
weak [Ki 38.8 uM] | ||||
yes [Ki 3.4 uM] | ||||
yes [Ki 3.7 uM] | yes (co-administration study) Comment: [PMID: 10759690]: Ki = 1.2 uM |
|||
yes |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
yes | ||||
yes | ||||
yes | ||||
yes | ||||
yes | ||||
yes | yes (co-administration study) Comment: Coadministration with Ergoloid mesylates: AUC decreased 30.4% |
PubMed
Title | Date | PubMed |
---|---|---|
Drug-induced thrombotic microangiopathy: incidence, prevention and management. | 2001 |
|
Indobufen: an updated review of its use in the management of atherothrombosis. | 2001 |
|
Novel platelet inhibitors. | 2001 |
|
The use of antiplatelet agents in acute cardiac care. | 2001 Apr |
|
Clinical application of procedural platelet monitoring during percutaneous coronary intervention among patients at increased bleeding risk. | 2001 Apr |
|
Relative contributions of CYP2C9 and 2C19 to phenytoin 4-hydroxylation in vitro: inhibition by sulfaphenazole, omeprazole, and ticlopidine. | 2001 Apr |
|
[Optimal platelet inhibition therapy in unstable angina pectoris and after coronary interventions]. | 2001 Apr |
|
[Pathophysiology of platelet activation and pharmacology of GPIIb/IIIa inhibitors]. | 2001 Apr |
|
Extracorporeal shockwave lithotripsy in patients treated with antithrombotic agents. | 2001 Apr |
|
[Pressure wire guide provisional coronary stent implantation]. | 2001 Apr |
|
Clinical and angiographical follow-up after implantation of a 6--12 microCi radioactive stent in patients with coronary artery disease. | 2001 Apr |
|
Results of CURE trial for acute coronary syndrome. | 2001 Apr 11 |
|
Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials. | 2001 Apr 17 |
|
Newer antiplatelet therapies in stroke prevention. | 2001 Feb |
|
[Late stent thrombosis after intracoronary brachytherapy. A case report and review of the literature]. | 2001 Feb |
|
Protective effects of SM-20302, an orally active GPIIb/IIIa antagonist, in an ADP/epinephrine-induced guinea pig model of transient cerebral ischemia. | 2001 Feb 1 |
|
Comparison of effects of clopidogrel versus ticlopidine on platelet function in patients undergoing coronary stent placement. | 2001 Feb 1 |
|
Fatal aplastic anaemia associated with clopidogrel. | 2001 Feb 10 |
|
Combination therapy with aspirin plus clopidogrel versus aspirin plus ticlopidine for prevention of subacute thrombosis after successful native coronary stenting. | 2001 Feb 15 |
|
Sustained benefit over four years from an initial combined antiplatelet regimen after coronary stent placement in the ISAR trial. Intracoronary Stenting and Antithrombotic Regimen. | 2001 Feb 15 |
|
[Update on the treatment with platelet antiaggregation agents]. | 2001 Jan |
|
[The new limitations of the Italian Regulatory Agency on Drugs]. | 2001 Jan |
|
Stasis ulcers refractory to therapy--accelerated healing by treatment with clopidogrel +/- dalteparin: a preliminary report. | 2001 Jan |
|
Fixed drug eruption from ticlopidine, with positive lesional patch test. | 2001 Jan |
|
Angioplasty increases coronary sinus F2-isoprostane formation: evidence for in vivo oxidative stress during PTCA. | 2001 Jan |
|
[Leukocytoclastic vasculitis associated with ticlopidine]. | 2001 Jan |
|
Antithrombotic therapy in cardiac stent patients. | 2001 Jan |
|
Diabetes mellitus with left transverse sinus thrombosis and right transverse sinus aplasia. | 2001 Jan |
|
Effects of cilostazol on late lumen loss and repeat revascularization after Palmaz-Schatz coronary stent implantation. | 2001 Jan |
|
Active-control trials: how would a new agent compare with placebo? A method illustrated with clopidogrel, aspirin, and placebo. | 2001 Jan |
|
Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement. | 2001 Jan |
|
[2 platelet inhibitors administered at the same time. Improved prognosis in myocardial infarct?]]. | 2001 Jan 11 |
|
Local delivery of enoxaparin to decrease restenosis after stenting: results of initial multicenter trial: Polish-American Local Lovenox NIR Assessment study (The POLONIA study). | 2001 Jan 2 |
|
Superiority of clopidogrel versus aspirin in patients with prior cardiac surgery. | 2001 Jan 23 |
|
Localized intracoronary gamma-radiation therapy to inhibit the recurrence of restenosis after stenting. | 2001 Jan 25 |
|
[Cholestatic hepatitis by ticlopidin]. | 2001 Jan 27 |
|
Febrile pancytopenia associated with clopidogrel. | 2001 Jan 8 |
|
The role of adenosine 5'-diphosphate receptor blockade in patients with cardiovascular disease. | 2001 Jul |
|
Extensive thrombus prior to elective percutaneous coronary intervention. | 2001 Jul |
|
Diffuse alveolar hemorrhage after clopidogrel use. | 2001 Jul |
|
Efficacy and safety of ticlopidine monotherapy versus ticlopidine and aspirin after coronary artery stenting: follow-up results of a randomized study. | 2001 Jun |
|
Platelet aggregation inhibition with ticlopidine in the treatment of stroke. | 2001 Mar |
|
[Pharmacy clinics. Medication of the month. Clopidogrel (Plavix)]. | 2001 Mar |
|
Pharmacokinetic differences between lansoprazole enantiomers and contribution of cytochrome P450 isoforms to enantioselective metabolism of lansoprazole in dogs. | 2001 Mar |
|
Metabolic characterization of the major human small intestinal cytochrome p450s. | 2001 Mar |
|
[Superiority of clopidogrel versus aspirin in patients with prior cardiac surgery]. | 2001 May |
|
The inhibition of oxygen radical release from human neutrophils by resting platelets is reversed by administration of acetylsalicylic acid or clopidogrel. | 2001 May |
|
Effect of cilostazol on restenosis after coronary angioplasty and stenting in comparison to conventional coronary artery stenting with ticlopidine. | 2001 May |
|
Edge stenosis after intracoronary radiotherapy: angiographic, intravascular, and histological findings. | 2001 May 1 |
|
P2y(12), a new platelet ADP receptor, target of clopidogrel. | 2001 May 4 |
Sample Use Guides
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/8780663
Following preparation of the platelet concentrate, 1.2 mL of ThromboSol was added to some units (treated units) through a sterile port. We then resuspended the
treated PC by gentle massaging and directly placed it at 4°C without shaking. The resulting treated PC contained the following reagents: amiloride (0.25 mM), adenosine (0.1 mM), SNP (50 mkM), dipyridamole (40 mkM) Ticlopidine (0.75 mkM), and quinacrine (0.2 mkM). In parallel, platelet concentrate were stored as control units at 22°C with shaking or at 4°C without shaking. After storage, aliquots of control and treated platelet concentrate were harvested for analysis as follows. The platelet concentrate to be sampled was gently massaged to achieve a homogenous cell suspension, and, by using a syringe with an 18-gauge needle, a 3-mL sample of platelets was removed via the sterile port. We then placed the platelet sample in a 15-mL polypropylene conical tube and centrifuged it at 950 x g for 20 minutes at 22°C to remove the
ThromboSol. The resulting platelet pellet was resuspended to the original sample volume with autologous platelet-poor plasma (PPP) and the platelet count was determined with a hematology analyzer
Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Jul 05 23:12:59 UTC 2023
by
admin
on
Wed Jul 05 23:12:59 UTC 2023
|
Record UNII |
OM90ZUW7M1
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NDF-RT |
N0000175578
Created by
admin on Wed Jul 05 23:12:59 UTC 2023 , Edited by admin on Wed Jul 05 23:12:59 UTC 2023
|
||
|
NCI_THESAURUS |
C80483
Created by
admin on Wed Jul 05 23:12:59 UTC 2023 , Edited by admin on Wed Jul 05 23:12:59 UTC 2023
|
||
|
LIVERTOX |
NBK548038
Created by
admin on Wed Jul 05 23:12:59 UTC 2023 , Edited by admin on Wed Jul 05 23:12:59 UTC 2023
|
||
|
NDF-RT |
N0000008832
Created by
admin on Wed Jul 05 23:12:59 UTC 2023 , Edited by admin on Wed Jul 05 23:12:59 UTC 2023
|
||
|
WHO-ATC |
B01AC05
Created by
admin on Wed Jul 05 23:12:59 UTC 2023 , Edited by admin on Wed Jul 05 23:12:59 UTC 2023
|
||
|
NDF-RT |
N0000008832
Created by
admin on Wed Jul 05 23:12:59 UTC 2023 , Edited by admin on Wed Jul 05 23:12:59 UTC 2023
|
||
|
WHO-VATC |
QB01AC05
Created by
admin on Wed Jul 05 23:12:59 UTC 2023 , Edited by admin on Wed Jul 05 23:12:59 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID5023669
Created by
admin on Wed Jul 05 23:12:59 UTC 2023 , Edited by admin on Wed Jul 05 23:12:59 UTC 2023
|
PRIMARY | |||
|
9588
Created by
admin on Wed Jul 05 23:12:59 UTC 2023 , Edited by admin on Wed Jul 05 23:12:59 UTC 2023
|
PRIMARY | |||
|
55142-85-3
Created by
admin on Wed Jul 05 23:12:59 UTC 2023 , Edited by admin on Wed Jul 05 23:12:59 UTC 2023
|
PRIMARY | |||
|
TICLOPIDINE
Created by
admin on Wed Jul 05 23:12:59 UTC 2023 , Edited by admin on Wed Jul 05 23:12:59 UTC 2023
|
PRIMARY | |||
|
OM90ZUW7M1
Created by
admin on Wed Jul 05 23:12:59 UTC 2023 , Edited by admin on Wed Jul 05 23:12:59 UTC 2023
|
PRIMARY | |||
|
7307
Created by
admin on Wed Jul 05 23:12:59 UTC 2023 , Edited by admin on Wed Jul 05 23:12:59 UTC 2023
|
PRIMARY | |||
|
10594
Created by
admin on Wed Jul 05 23:12:59 UTC 2023 , Edited by admin on Wed Jul 05 23:12:59 UTC 2023
|
PRIMARY | RxNorm | ||
|
2657
Created by
admin on Wed Jul 05 23:12:59 UTC 2023 , Edited by admin on Wed Jul 05 23:12:59 UTC 2023
|
PRIMARY | |||
|
D013988
Created by
admin on Wed Jul 05 23:12:59 UTC 2023 , Edited by admin on Wed Jul 05 23:12:59 UTC 2023
|
PRIMARY | |||
|
259-498-5
Created by
admin on Wed Jul 05 23:12:59 UTC 2023 , Edited by admin on Wed Jul 05 23:12:59 UTC 2023
|
PRIMARY | |||
|
5472
Created by
admin on Wed Jul 05 23:12:59 UTC 2023 , Edited by admin on Wed Jul 05 23:12:59 UTC 2023
|
PRIMARY | |||
|
M10855
Created by
admin on Wed Jul 05 23:12:59 UTC 2023 , Edited by admin on Wed Jul 05 23:12:59 UTC 2023
|
PRIMARY | Merck Index | ||
|
OM90ZUW7M1
Created by
admin on Wed Jul 05 23:12:59 UTC 2023 , Edited by admin on Wed Jul 05 23:12:59 UTC 2023
|
PRIMARY | |||
|
100000092003
Created by
admin on Wed Jul 05 23:12:59 UTC 2023 , Edited by admin on Wed Jul 05 23:12:59 UTC 2023
|
PRIMARY | |||
|
C61972
Created by
admin on Wed Jul 05 23:12:59 UTC 2023 , Edited by admin on Wed Jul 05 23:12:59 UTC 2023
|
PRIMARY | |||
|
SUB11028MIG
Created by
admin on Wed Jul 05 23:12:59 UTC 2023 , Edited by admin on Wed Jul 05 23:12:59 UTC 2023
|
PRIMARY | |||
|
CHEMBL833
Created by
admin on Wed Jul 05 23:12:59 UTC 2023 , Edited by admin on Wed Jul 05 23:12:59 UTC 2023
|
PRIMARY | |||
|
DB00208
Created by
admin on Wed Jul 05 23:12:59 UTC 2023 , Edited by admin on Wed Jul 05 23:12:59 UTC 2023
|
PRIMARY | |||
|
3908
Created by
admin on Wed Jul 05 23:12:59 UTC 2023 , Edited by admin on Wed Jul 05 23:12:59 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLIC ENZYME -> INHIBITOR | |||
|
SALT/SOLVATE -> PARENT | |||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
METABOLIC ENZYME -> INHIBITOR | |||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
METABOLIC ENZYME -> INHIBITOR | |||
|
METABOLIC ENZYME -> SUBSTRATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT | |||
|
METABOLITE -> PARENT | |||
|
METABOLITE -> PARENT |
IN VITRO
|
||
|
METABOLITE -> PARENT |
IN VITRO
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |